

## 2023 Current Fiscal Year Report: Allergenic Products Advisory Committee

Report Run Date: 03/29/2024 02:03:20 AM

**1. Department or Agency**

Department of Health and Human  
Services

**2. Fiscal Year**

2023

**3. Committee or Subcommittee**

Allergenic Products Advisory  
Committee

**3b. GSA Committee  
No.**

784

**4. Is this New During Fiscal Year?** **5. Current Charter** **6. Expected Renewal Date** **7. Expected Term Date**

No 07/09/2022 07/09/2024

**8a. Was Terminated During Fiscal Year?** **8b. Specific Termination Authority**

No

**8c. Actual  
Term Date**

**9. Agency Recommendation for Next Fiscal Year**

Continue

**10a. Legislation Req to Terminate?**

Not Applicable

**10b. Legislation Pending?**

Not Applicable

**11. Establishment Authority** Authorized by Law

**12. Specific Establishment Authority**

21 U.S.C. 394

**13. Effective Date**

11/28/1990

**14. Committee Type**

Continuing

**14c. Presidential?**

No

**15. Description of Committee** Scientific Technical Program  
Advisory Board

**16a. Total Number of Reports**

No Reports for  
this Fiscal Year

**17a. Open** 0 **17b. Closed** 0 **17c. Partially Closed** 0 **Other Activities** 0 **17d. Total** 0

**Meetings and Dates**

No Meetings

Current FY Next FY

<b>18a(1). Personnel</b>		
<b>Pmts to Non-Federal Members</b>	\$0.00	\$4,912.00
<b>18a(2). Personnel</b>		
<b>Pmts to Federal Members</b>	\$0.00	\$0.00
<b>18a(3). Personnel</b>	\$289,971.00	\$312,992.00
<b>Pmts to Federal Staff</b>		
<b>18a(4). Personnel</b>		
<b>Pmts to Non-Member Consultants</b>	\$0.00	\$6,141.00
<b>18b(1). Travel and Per Diem to Non-Federal Members</b>		
	\$0.00	\$0.00
<b>18b(2). Travel and Per Diem to Federal Members</b>		
	\$0.00	\$0.00
<b>18b(3). Travel and Per Diem to Federal Staff</b>		
	\$0.00	\$0.00
<b>18b(4). Travel and Per Diem to Non-member Consultants</b>		
	\$0.00	\$0.00
<b>18c. Other(rents,user charges, graphics, printing, mail, etc.)</b>	\$72,493.00	\$78,248.00
<b>18d. Total</b>	\$362,464.00	\$402,293.00
<b>19. Federal Staff Support Years (FTE)</b>		
	1.60	1.60

**20a. How does the Committee accomplish its purpose?**

The Committee reviews and evaluates data concerning the safety, effectiveness, and adequacy of labeling of marketed and investigational allergenic biological products or materials that are administered to humans for the diagnosis, prevention or treatment of allergies and allergic disease, and makes appropriate recommendations to the Commissioner of Food

and Drugs of its findings regarding the affirmation or revocation of biological product licenses, on the safety, effectiveness, and labeling of the products, on clinical and laboratory studies of such products, on amendments or revisions to regulations governing the manufacture, testing and licensing of allergenic biological products, and on the quality and relevance of FDA's research programs which provide the scientific support for regulating these agents.

**20b. How does the Committee balance its membership?**

Members are selected from academic and clinical practice settings and include authorities in the areas of allergy, immunology, pediatrics, internal medicine, and biochemistry. One member is technically qualified and identified with consumer interests. The Committee may also include one non-voting member to represent industry's interests.

**20c. How frequent and relevant are the Committee Meetings?**

In FY 2023, no Advisory Committee meetings were held. It is anticipated that the Committee will meet at least once in FY 2024.

**20d. Why can't the advice or information this committee provides be obtained elsewhere?**

Members of the Committee are drawn from academia, research, and/or clinical practice. Their advice and input lends credibility to regulatory decisions made and helps those decisions stand up to intense public scrutiny. The alternate means of obtaining this advice would involve the recruitment of large numbers of scientists on a full-time basis at maximum rates of compensations.

## 20e. Why is it necessary to close and/or partially closed committee meetings?

There were no open or closed meetings to report for FY23.

## 21. Remarks

Although this committee did not meet in FY 2023, time was devoted to reviewing applications for new nominees, maintaining associated records for these activities, and streamlining paper processes within FDA. In addition, time was spent in the routine care and maintenance of the committee: the development of a financial report for this website; updating the roster and number of vacancies on our website; completing the annual ethics report; reviewing financial disclosures of current members and providing ethics training. Since the Committee did not meet, no reporting was required. Dr. Jay Portnoy transferred from APAC over to VRBPAC effective 2.1.2022.

## Designated Federal Officer

Valerie Vashio DFO

Committee Members	Start	End	Occupation	Member Designation
Assa'ad, Amal	03/23/2016	08/31/2024	Professor of Pediatrics, Cincinnati Children's Hospital Medical Center	Special Government Employee (SGE) Member
Davis, Carla	09/01/2021	08/31/2025	Professor of Pediatrics, Baylor College of Medicine	Special Government Employee (SGE) Member
Dykewicz, Mark	12/18/2019	08/31/2023	Professor of Internal Medicine, Saint Louis University School of Medicine	Special Government Employee (SGE) Member

Greenberger, Paul	06/19/2019	08/31/2023	Professor of Medicine Division of Allergy and Immunology, Northwestern University	Special Government Employee (SGE) Member
Nolte, Hendrik	04/22/2020	08/31/2023	Senior VP, Respiratory & Immunology, Merck	Representative Member
Peden, David	09/01/2014	08/31/2024	Harry S. Andrews Distinguished Professor of Pediatrics, University of North Carolina School of Medicine	Special Government Employee (SGE) Member
Woodfolk, Judith	07/23/2020	08/31/2024	Professor of Medicine & Microbiology, University of Virginia Health System	Special Government Employee (SGE) Member

## Number of Committee Members Listed: 7

### Narrative Description

FDA's strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical products; establish an effective tobacco regulation, prevention, and control program; and management for organizational excellence and accountability. The Allergenic Products Advisory Committee supports FDA's mission and strategic action plan by reviewing and evaluating available data relating to the safety, effectiveness, and adequacy of labeling of marketed and investigational allergenic biological products or materials that are administered to humans for the diagnosis, prevention or treatment of allergies and allergic disease. The Committee also considers the quality and relevance

of FDA's research program, which provides scientific support for the regulation of these products. The Committee supports FDA's mission by using science-based risk management in all of its activities. The Committee recommendations provide the most health promotion and protection at the least cost for the public. This Committee assists the Agency in ensuring timely, high quality, cost-effective processes for review of new technologies/pre-market submissions, effective communication and working relationships with stakeholders to enhance U.S. and global health outcomes, accurately analyzing risks associated with medical products, facilitating the development and availability of medical countermeasures to limit the effects of a terrorist attack on the civilian and military populations, protecting the safety and security of biologics are all key components of FDA's strategic plan objectives.

**What are the most significant program outcomes associated with this committee?**

	Checked if Applies
Improvements to health or safety	<input checked="" type="checkbox"/>
Trust in government	<input checked="" type="checkbox"/>
Major policy changes	<input checked="" type="checkbox"/>
Advance in scientific research	<input checked="" type="checkbox"/>
Effective grant making	<input type="checkbox"/>
Improved service delivery	<input type="checkbox"/>
Increased customer satisfaction	<input checked="" type="checkbox"/>
Implementation of laws or regulatory requirements	<input checked="" type="checkbox"/>
Other	<input type="checkbox"/>

**Outcome Comments**

NA

**What are the cost savings associated with this committee?**

	Checked if Applies
None	<input type="checkbox"/>
Unable to Determine	<input checked="" type="checkbox"/>

Under \$100,000	<input type="checkbox"/>
\$100,000 - \$500,000	<input type="checkbox"/>
\$500,001 - \$1,000,000	<input type="checkbox"/>
\$1,000,001 - \$5,000,000	<input type="checkbox"/>
\$5,000,001 - \$10,000,000	<input type="checkbox"/>
Over \$10,000,000	<input type="checkbox"/>
Cost Savings Other	<input type="checkbox"/>

### **Cost Savings Comments**

The utilization of the Allergenic Products Advisory Committee enables the Agency to obtain required and frequently scarce professional services from medical and scientific experts not otherwise available to the Agency; and to obtain the services of these experts only on an as needed basis rather than on a full time basis. The service of the Committee results in advice for the improvement of the public health for which it is difficult to assign a financial value.

**What is the approximate Number of recommendations produced by this committee for the life of the committee?**

21

### **Number of Recommendations Comments**

The Committee made 21 recommendations from FY2003 through FY2023.

**What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?**

84%

### **% of Recommendations Fully Implemented Comments**

The function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice.

**What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?**

16%

### **% of Recommendations Partially Implemented Comments**

The function of an advisory committee is purely advisory in nature. Although the FDA

most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice.

**Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?**

Yes ☒ No ☐ Not Applicable ☐

**Agency Feedback Comments**

The Agency usually does. Product approval issues are first released to the sponsor. When appropriate, information is made available to the public. Actions related to guidance documents or other general matters issues are available publicly when implemented.

**What other actions has the agency taken as a result of the committee's advice or recommendation?**

Checked if Applies

Reorganized Priorities	<input checked="" type="checkbox"/>
Reallocated resources	<input checked="" type="checkbox"/>
Issued new regulation	<input checked="" type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input checked="" type="checkbox"/>

**Action Comments**

FDA approves or chooses not to approve investigational new medical products.

**Is the Committee engaged in the review of applications for grants?**

No

**Grant Review Comments**

NA

**How is access provided to the information for the Committee's documentation?**

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input checked="" type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>



Publications



Other



**Access Comments**

NA